Efficacy of sarilumab and dexamethasone co-administration for lowering multiple blood biomarkers in the treatment of cytokine release syndrome in hospitalized covid-19 patients
The current study was planned to explore the potential synergistic role of the co-administration of sarilumab and dexamethasone in reducing blood biomarkers associated with cytokine release syndrome in hospitalised patients of coronavirus disease-2019. The sample comprised 22 patients hospitalised...
Saved in:
| Main Authors: | Ishtiaq Ahmad, Hamidullah |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pakistan Medical Association
2024-06-01
|
| Series: | Journal of the Pakistan Medical Association |
| Subjects: | |
| Online Access: | https://jpma.org.pk/index.php/public_html/article/view/10480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01) -
The efficacy and safety of sarilumab, fully human monoclonal antibodies against interleukin 6 receptor, in rheumatoid arthritis: new evidence
by: E. L. Nasonov, et al.
Published: (2019-11-01) -
Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01) -
Treatment of indolent systemic mastocytosis with sarilumab is not supported in a randomized trial
by: Hirsh D. Komarow, MD, et al.
Published: (2025-08-01) -
Cellulose-Based Scaffolds with Prolonged Dexamethasone Release for Bone Tissue Engineering
by: Jolanta Liesienė, et al.
Published: (2025-06-01)